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Relationship between atrial fibrillation
and blunted hyperemic myocardial blood flow
in patients with hypertrophic cardiomyopathy
Roberto Sciagra`, MD,a Barbara Sotgia, MD,a Iacopo Olivotto, MD,b
Franco Cecchi, MD,b Stefano Nistri, MD,b Paolo G. Camici, MD, FACC, FESC,
FAHA, FRCP,c and Alberto Pupi, MDa
Background. Atrial fibrillation (AF) and coronary microvascular dysfunction (CMD) are
common in hypertrophic cardiomyopathy (HCM), but whether they are associated is unclear.
We assessed the relationship between AF and CMD in HCM.
Methods and Results. Global hyperemic myocardial blood flow (hMBF) was measured in 95
HCM patients (16 with, 79 without paroxysmal or chronic AF) by N-13 ammonia positron
emission tomography (PET) after dipyridamole infusion. AF patients were older (50.5 ± 13.4
vs. 38.7 ± 14.9 years, P < .0005), had larger left atrial diameter (49.8 ± 7.4 vs 38.6 ± 5.7 mm,
P < .00001), and left ventricular end-systolic diameter (30.4 ± 6.7 vs 25.5 ± 5.3 mm, P < .005)
compared with those in stable sinus rhythm. In patients with AF, hMBF was significantly lower
(1.23 ± 0.44 vs 1.87 ± 0.90 mL/min/g, P < 0.0001). In multivariate logistic regression analysis,
hMBF, left atrial diameter, and age were independently associated with AF (P < .05 for all).
Conclusions. HCM patients with paroxysmal or chronic AF have lower hMBF than those
in stable sinus rhythm. The association between CMD and AF is independent of other known
predictors of AF, suggesting a causal link between these two features. (J Nucl Cardiol
2009;16:92–6)
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INTRODUCTION
Atrial fibrillation (AF) is among the most common
complications of hypertrophic cardiomyopathy (HCM),
occurring in over 20% of unselected patients, and usually
implies an adverse prognosis due to increased prevalence
of heart failure-related complications.1,2 Among the
various parameters that have been suggested as deter-
minants for development of AF, left atrial dimensions
and function are considered the most important.2,3
Coronary microvascular dysfunction (CMD), doc-
umented by positron emission tomography (PET) as a
blunted response of myocardial blood flow to pharma-
cologically induced hyperemia (hMBF), is also a well-
known feature of HCM.4,5 CMD has been identified as a
powerful predictor of adverse outcome due to heart
failure progression and death in HCM patients.6-9 To
date, it is unknown whether AF and CMD are associ-
ated, and whether the clinical consequences of CMD
may be partly mediated by increased susceptibility to
arrhythmia. Thus, the aim of the present study was to
explore the possible relationship between these two
unfavorable features in a large HCM patient cohort
studied by PET.
METHODS
Patient Population
The study cohort included 95 patients (66 males and 29
females; age 40.7 ± 15.3 years, range 11-74) from the popu-
lation followed by physicians with expertise and long-
standing interest in HCM at our Regional Referral Center.
The diagnosis of HCM was based on the echocardiographic
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evidence of a hypertrophied and non-dilated left ventricle
(LV) (wall thickness C15 mm) in the absence of any other
known cardiac or systemic cause of LV hypertrophy.1 Coro-
nary artery disease was excluded in HCM patients at the time
of enrollment by maximal, symptom-limited treadmill or
cycloergometer exercise test (performed routinely in our
HCM patients), followed by coronary angiography in patients
with a positive or dubious test result. Furthermore, patients
with diabetes or actively treated hypertension were excluded.
All patients gave informed consent to participate in the study,
which was approved by the Ethics Committees of our
Institution.
Definition of Atrial Fibrillation
Documentation of AF was based on ECG recordings
obtained either following acute onset of symptoms, or during
routine medical examination. For the purpose of the present
study, AF was defined as paroxysmal when either self-termi-
nating or successfully cardioverted to sinus rhythm; AF was
considered chronic when it became permanent.
Positron Emission Tomography
All PET scans were performed after an appropriate period
of pharmacologic washout using an already described proce-
dure.4,10 Briefly, patients were positioned on the PET scanner
and a transmission scan was recorded. Then, dipyridamole was
administered intravenously (0.56 mg/kg of body weight/
4 minutes).4 After 3 minutes of dipyridamole infusion, a bolus
of 370 MBq of nitrogen-13 ammonia (N-13 ammonia) diluted
in 10 mL saline solution was injected intravenously over a
period of 15 to 20 seconds. A dynamic scan was acquired for
the duration of 4 minutes, followed by a prolonged static
acquisition of 15 minutes. MBF was calculated from the
dynamic data by fitting the arterial input function and tissue
time-activity curves to a compartmental model for N-13
ammonia and the average hMBF for the entire LV was
obtained.11 We did not measure baseline MBF in order to
minimize patient exposure, taking into account that previous
studies demonstrate that this parameter is not significantly
different between HCM patients and healthy controls4 and that
hMBF is superior to coronary flow reserve in predicting LV
remodeling and outcome in HCM patients.8,9 All studies were
analyzed by expert observers, completely unaware of the
patient clinical and echocardiographic data.
Echocardiography
All patients underwent baseline echocardiography at the
time of positron emission tomography. Echocardiographic
studies were performed with commercially available instru-
ments. Standard measurements of left atrial, LV end-diastolic,
and end-systolic diameter were obtained in the parasternal
long-axis view.12 Obstruction of the LV outflow was consid-
ered present when a peak outflow gradient of C30 mm Hg was
present under baseline conditions.1
Statistical Analysis
Results are shown as mean ± standard deviation. The
comparisons between groups were performed by the Student
t-test for unpaired samples. The comparison of proportions was
performed with the Fisher’s exact test or the Yates corrected
chi-square, as appropriate. Multivariate logistic regression
analysis to identify independent predictors of AF was per-
formed by a forward-stepwise algorithm, with the entry
probability for each variable set at 0.05. A P-value \.05 was
considered statistically significant. All calculations were per-
formed using the SPSS statistical package version 12.0.
RESULTS
Clinical and Echocardiographic Features
Patients predominantly had mild or no symptoms
(New York Heart Association Class I in 50, Class II in
40, and Class III in 5 patients only). Mean left atrial
diameter was 40.4 ± 7.4 mm. In 71 patients the left
atrial diameter was \45 mm, and in 7 it was [50 mm.
Maximal LV wall thickness measured by echocardiog-
raphy was 23 ± 6 mm. LV end-diastolic and end-
systolic diameters were 44 ± 5 mm and 26 ± 5 mm,
respectively. Eleven patients had dynamic LV outflow
obstruction (C30 mm Hg) in resting conditions. None
had LV systolic dysfunction (i.e., were in the end-stage
phase) or more than mild-to-moderate mitral
regurgitation.
Atrial Fibrillation
Overall, 16 patients had documented AF (17%) at
the time of PET. Of these, 12 had a history of one or
more paroxysms of AF, but were in sinus rhythm at the
time of enrolment. The remaining 4 patients were in
chronic AF. In 4 patients, AF occurred despite a left
atrial diameter \45 mm. The clinical, echocardio-
graphic, and hemodynamic features of the 16 patients
with AF vs the 79 patients in stable sinus rhythm are
described in Table 1. AF patients were significantly
older, had a slightly worse New York Heart Association
class distribution, clearly larger atrial diameter, signifi-
cantly larger LV end-systolic diameter, and lower
ejection fraction.
Relationship Between hMBF and Atrial
Fibrillation
Average hMBF for the entire LV was 1.76 ±
0.87 mL/min/g (range 0.59 to 5.57 mL/min/g). In patients
with AF, hMBF was significantly lower compared to those
in stable sinus rhythm (1.23 ± 0.44 mL/min/g vs 1.87 ±
0.90 mL/min/g, respectively; P \ .0001) (Figure 1).
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Such difference remained significant when only the
patients with normal or mildly enlarged left atrium
(\45 mm) were examined: 0.95 ± 0.37 mL/min/g in the
AF group vs 1.87 ± 0.88 mL/min/g in the group in sinus
rhythm, P \ .05. Specifically, in the four patients with AF
and a left atrial diameter \45 mm, hMBF was very
severely impaired, ranging from 0.59 mL/min/g to
1.31 mL/min/g. The proportion of patients with AF in the
lowest (B1.29 mL/min/g) and middle (1.30-1.89 mL/
min/g) tertiles of hMBF was 13- and 5.5-fold greater,
respectively, compared with those with relatively pre-
served flow in the highest tertile ([1.89 mL/min/g)
(Figure 2).
At univariate logistic regression analysis, AF was
significantly associated with hMBF, age, New York
Heart Association class, left atrial diameter, LV end-
systolic diameter, and LV ejection fraction. Conversely,
no significant relation was found with LV wall thickness
and end-diastolic diameter, or with resting LV outflow
obstruction. In a multivariate model including all the
significant variables at univariate analysis and using a
forward-stepwise procedure, the association of AF with
hMBF remained significant (P \ .03, model v2 38.1)
and independent of the other two selected variables, i.e.,
left atrial diameter (P \ .00001, model v2 27.5) and age
(P \ 0.03, model v2 32.8). The R2 of the final model
was 0.56.
DISCUSSION
The main finding of the present investigation is that
HCM patients with paroxysmal or chronic AF have a
Table 1. Comparison of clinical and echocardiographic variables in patients with history of AF vs those
without
AF No AF P
Age 50.5 ± 13.4 years 38.7 ± 14.9 years \.0005
Male 14 (88%) 52 (66%) NS
Angina 5 (31%) 24 (30%) NS
Dyspnea 8 (50%) 29 (37%) NS
NYHA functional class (I/II/III) 4 (25%)/10 (63%)/2 (12%) 46 (58%)/30 (38%)/3 (4%) \.05
Left atrial diameter 49.8 ± 7.4 mm 38.6 ± 5.7 mm \.00001
LV wall thickness 22.9 ± 4 mm 23 ± 6.5 mm NS
LV end-diastolic diameter 45.5 ± 5.3 mm 43.7 ± 4.9 mm NS
LV end-systolic diameter 30.4 ± 6.7 mm 25.5 ± 5.3 mm \.005
LV ejection fraction 62 ± 19% 72 ± 10% \.01
LV outflow obstruction 15.6 ± 19.4 mmHg 13.4 ± 17.7 mmHg NS
Baseline
Heart rate (beats/min) 69 ± 15 63 ± 10 NS
Systolic blood pressure (mmHg) 101 ± 15 114 ± 18 NS
Diastolic blood pressure (mmHg) 69 ± 11 70 ± 10 NS
Dipyridamole
Heart rate (beats/min) 81 ± 19 88 ± 17 NS
Systolic blood pressure (mmHg) 105 ± 20 112 ± 14 NS
Diastolic blood pressure (mmHg) 65 ± 14 68 ± 9 NS
AF, Atrial fibrillation; LV, left ventricular; NYHA, New York Heart Association.
Figure 1. Comparison of hMBF in patients with AF vs those
without. Circles represent the individual data points; lines
represent mean ± standard deviation.
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substantially more severe impairment of coronary
microvascular function than patients in stable sinus
rhythm. In our cohort, the proportion of patients with AF
in the lowest tertile of hMBF was 13-fold greater than
that in the highest tertile. Of note, the association
between AF and CMD proved to be independent of other
well-known, powerful predictors of AF such as left atrial
dimensions and age, and remained significant when only
those patients with normal or mildly enlarged left atrium
were analyzed.
These findings have potentially relevant implica-
tions. First, the concomitant presence of more severe
CMD in HCM patients with AF reinforces the adverse
prognostic significance of arrhythmia, and suggests a
synergistic mechanism of these two unfavorable features
in determining disease progression and adverse out-
come.1,2,13-17 Specifically, the severely blunted hMBF
observed in AF patients might reflect more aggressive
disease expression involving not only the LV but also
the atrial myocardium, causing atrial dysfunction and
AF.3,15
Second, and of particular relevance, our observa-
tions suggest the novel concept that, rather than just
coexisting independently, CMD and AF might be
directly linked in HCM patients. The fact that the sta-
tistical association in our cohort was independent of a
powerful predictor of AF such as left atrial size strongly
supports such connection. Indeed, the intriguing sub-
group of patients who developed AF despite normal or
only mildly enlarged left atrial size suggests the possi-
bility that arrhythmia may be directly related to CMD,
and not necessarily mediated by an advanced disease
state, nor by extensive left atrial remodeling.
Among the mechanisms that can be proposed to
explain the association of CMD and AF, the most likely
involves recurrent ischemia leading to abrupt worsening
of LV (prevalently diastolic) function, increased LV
filling pressures and left atrial stretch, finally triggering
AF. Similar mechanisms have also been proposed to
explain AF onset in the context of acute coronary syn-
dromes, an occurrence also associated with adverse
prognostic significance.18,19 The present hypothesis has
recently found support in the observation that ST-T
segment abnormalities during exercise stress testing in
HCM patients predict subsequent occurrence of AF,20
suggesting that inducible ischemia does play a role in
this regard. Other potential mechanisms may include
more diffuse and substantial collagen metabolism
abnormalities favoring atrial fibrosis and arrhythmoge-
neicity, and recurrent mitral regurgitation, caused by
regional ischemic LV dysfunction, ultimately reflecting
upon left atrium structure and function.3 Finally, it is
possible that AF may represent a direct consequence of
atrial ischemia due to dysfunction of the atrial micro-
circulation. To date, however, these mechanisms remain
speculative.3,15 Unfortunately, a number of technical
limitations of currently available PET scanners, includ-
ing their limited spatial resolution, did not allow
appropriate assessment of atrial MBF.
Of note, the profile of the present study cohort is
relatively benign, with regard to prevalence of resting
LV outflow obstruction and severity of congestive
symptoms, compared to other reported in the literature.1
However, there was no particular attempt to exclude
patients with more severe disease in the present study,
the features of our patients pointing rather to the absence
of significant selection bias.21 The fact that PET proved
predictive in this patient cohort, perceived to be at
somewhat lower risk of events including arrhythmias,
strengthens the association between microvascular dys-
function and AF in HCM patients.
An unavoidable limitation of the present study lies
in the potential underestimation of the real prevalence of
AF, due to the occurrence of asymptomatic paroxysms
in patients otherwise considered to be in stable sinus
rhythm. However, the acute onset of paroxysmal AF is
poorly tolerated and generally associated with symptoms
in the vast majority of HCM patients, due to the pro-
found hemodynamic consequences of rapid ventricular
rates and the loss of atrial function upon a hypertrophic,
non-compliant left ventricle.2 Thus, we doubt that the
occurrence of asymptomatic AF may have significantly
affected our study findings.
In conclusion, this study demonstrates that HCM
patients with paroxysmal or chronic AF have a more
Figure 2. Scatterplot of left atrial diameter vs hMBF. Solid
circles represent the patients with AF, open circles the patients
without. The two horizontal lines represent the limits of hMBF
tertiles.
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severely blunted hMBF as compared to those in stable
sinus rhythm. The association between CMD and AF in
HCM patients seems independent of other known pre-
dictors of AF, such as left atrial enlargement and age,
raising the novel concept of a direct causal link between
these two unfavorable disease features. Further, pro-
spective investigations on patient population including a
larger number of arrhythmic patients are warranted to
define the mechanisms and clinical impact of the asso-
ciation between CMD and AF in HCM.
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